APLEXIS, INC.

WILMETTE, IL

Oncologysmall moleculeGrant-only

What changed

Study registered, no phase assigned: Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

7w agoTrial registeredMay 27, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

10,312 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $529k · non-dilutive
Jun 1, 2025
EMORY UNIVERSITY · PI YANG, JINGJING · NIA · award ends Mar 31, 2030 · Investigating Cis- and Trans-Genetic Regulation of Brain Transcriptomics and Proteomics Associated with AD/ADRD
NIH RePORTER · NIH RePORTER 11142778 (opens the source filing in a new tab)
Trial
Study registered
Apr 24, 2025
AORTIC VALVE DISEASES, Bicuspid Aortic Valve (BAV) · RECRUITING · sponsor: Xijing Hospital · Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China
ClinicalTrials.gov · NCT06830499 (opens the source filing in a new tab)
Grant
R01 · $462k · non-dilutive
Mar 1, 2025
UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI YANG, JUN · NEI · award ends Feb 28, 2030 · The role of centriole linkage in retinal degeneration and hearing loss
NIH RePORTER · NIH RePORTER 11025390 (opens the source filing in a new tab)
Grant
R01 · $627k · non-dilutive
Jan 24, 2025
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI YANG, JING · NIEHS · award ends Nov 30, 2029 · Cytoplasmic remodeling during the vertebrate oocyte-to-embryo transition
NIH RePORTER · NIH RePORTER 11049710 (opens the source filing in a new tab)
Grant
R01 · $718k · non-dilutive
Jan 15, 2025
ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN · NCI · award ends Dec 31, 2029 · Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticity
NIH RePORTER · NIH RePORTER 11050940 (opens the source filing in a new tab)
Trial
NA registered
Oct 4, 2024
Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer · COMPLETED · sponsor: Washington University School of Medicine · Enhanced Assistance During Radiotherapy for Unmet Essential Needs
ClinicalTrials.gov · NCT06582849 (opens the source filing in a new tab)
Grant
R33 · $374k · non-dilutive
May 15, 2024
GEORGIA STATE UNIVERSITY · PI YANG, JENNY J. · NHLBI · award ends Apr 30, 2027 · Development of Protein MRI Contrast Agent for Precision Imaging Lung Fibrosis
NIH RePORTER · NIH RePORTER 11291381 (opens the source filing in a new tab)
Grant
K99 · $53k · non-dilutive
Apr 18, 2024
BOSTON CHILDREN'S HOSPITAL · PI SONG, JANET · NIMH · award ends Aug 31, 2025 · Genomic approaches to understand human neural specializations
NIH RePORTER · NIH RePORTER 11076755 (opens the source filing in a new tab)
Grant
R01 · $609k · non-dilutive
Apr 1, 2024
UNIVERSITY OF KENTUCKY · PI YANG, JIN-MING · NCI · award ends Mar 31, 2030 · Integrative Targeted Therapy for Melanoma
NIH RePORTER · NIH RePORTER 11060916 (opens the source filing in a new tab)
Grant
R21 · $213k · non-dilutive
Mar 1, 2024
UNIVERSITY OF KENTUCKY · PI YANG, JIN-MING · NCI · award ends Feb 28, 2027 · Novel Strategy to Augmenting Immunotherapy against Melanoma
NIH RePORTER · NIH RePORTER 11045672 (opens the source filing in a new tab)
Grant
K25 · $171k · non-dilutive
May 1, 2023
EMORY UNIVERSITY · PI YANG, JI (CARL) · NIDDK · award ends Apr 30, 2028 · Understanding Diabetes Heterogeneity via Mining Multimodality Interconnected Data
NIH RePORTER · NIH RePORTER 11082231 (opens the source filing in a new tab)
Grant
R44 · $1.1M · non-dilutive
Sep 15, 2022
APLEXIS, INC. · PI YANG, JING · NHLBI · award ends Feb 28, 2027 · Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis
NIH RePORTER · NIH RePORTER 11051837 (opens the source filing in a new tab)
Grant
R01 · $434k · non-dilutive
Mar 1, 2022
UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YANG, JING · NCI · award ends Feb 28, 2027 · Functional interplay between Hippo and estrogen receptor ESR1
NIH RePORTER · NIH RePORTER 11042246 (opens the source filing in a new tab)
Grant
R01 · $546k · non-dilutive
Sep 15, 2015
UNIVERSITY OF MISSISSIPPI MED CTR · PI FREEMAN, KEVIN B. · NIDA · award ends May 31, 2027 · Deterrents for prescription opioid abuse
NIH RePORTER · NIH RePORTER 11081630 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator YANG, JING is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.25same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China
7w agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Enhanced Assistance During Radiotherapy for Unmet Essential Needs
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Enhanced Assistance During Radiotherapy for Unmet Essential Needs
10mo agoTrial completedSource (opens the source filing in a new tab)
NIH R33 · $0.4M · Development of Protein MRI Contrast Agent for Precision Imaging Lung Fibrosis
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Investigating Cis- and Trans-Genetic Regulation of Brain Transcriptomics and Proteomics Associated with AD/ADRD
May 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Deterrents for prescription opioid abuse
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH K25 · $0.2M · Understanding Diabetes Heterogeneity via Mining Multimodality Interconnected Data
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Integrative Targeted Therapy for Melanoma
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Novel Strategy to Augmenting Immunotherapy against Melanoma
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH K99 · $0.1M · Genomic approaches to understand human neural specializations
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Functional interplay between Hippo and estrogen receptor ESR1
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R44 · $1.1M · Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis
Feb 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · The role of centriole linkage in retinal degeneration and hearing loss
Feb 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Cytoplasmic remodeling during the vertebrate oocyte-to-embryo transition
Jan 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticity
Jan 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

R01 · $529k · non-dilutive

Study registered

R01 · $462k · non-dilutive

R01 · $627k · non-dilutive

R01 · $718k · non-dilutive

NA registered

R33 · $374k · non-dilutive

K99 · $53k · non-dilutive

R01 · $609k · non-dilutive

R21 · $213k · non-dilutive

K25 · $171k · non-dilutive

R44 · $1.1M · non-dilutive

R01 · $434k · non-dilutive

R01 · $546k · non-dilutive